Alkermes plc. (ALKS)
Healthcare · Pharmaceutical Preparations
Alkermes plc. (ALKS) stock research on InvestAtlant: institutional ownership from 13F filings, insider Form 4 activity, and SEC context.
Top institutional holders (2026-Q2)
| Institution | Shares | Value | % Outstanding |
|---|---|---|---|
| BlackRock, Inc. | 29,235,739 | .53B | 17.45% |
| BAKER BROS. ADVISORS LP | 10,012,267 | $524.59M | 5.98% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 9,490,818 | $497.27M | 5.66% |
| State Street Corp | 9,160,575 | $479.97M | 5.47% |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,515,025 | $393.75M | 4.49% |
| T. Rowe Price Associates Inc | 6,737,328 | $353.0K | 4.02% |
| Renaissance Technologies LLC | 6,460,928 | $338.52M | 3.86% |
| GEODE CAPITAL MANAGEMENT, LLC | 4,477,876 | $234.66M | 2.67% |
Recent insider transactions
| Date | Insider | Title | Type | Value |
|---|---|---|---|---|
| 2026-09-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sale | $97.7K |
| 2026-09-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sale | $422.9K |
| 2026-08-17 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sale | $33.0K |
| 2026-08-17 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sale | $340.0K |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sale | $437.2K |
| 2026-08-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sale | $98.8K |
| 2026-08-03 | snyderman nancy lynn MD | Director | Sale | $2.24M |
| 2026-07-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sale | 09.9K |